Research Database

Peer-Reviewed
Evidence Library

Curated summaries of clinical trials, animal studies, and mechanistic research that inform every peptide profile on this platform.

18 studies indexed

New England Journal of Medicine

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

In this 68-week, double-blind, randomized trial of 1,961 adults, once-weekly semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% versus 2.4% with placebo, alongside improvements in cardiometabolic risk factors.

Semaglutide Human RCT
2021
Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002. View source
New England Journal of Medicine

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

A 72-week phase 3 trial of 2,539 adults without diabetes; the dual GIP/GLP-1 receptor agonist tirzepatide achieved mean weight reductions of up to 20.9% at the 15 mg dose, the largest yet reported for a pharmacologic agent at the time.

Tirzepatide Human RCT
2022
Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216. View source
New England Journal of Medicine

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Retatrutide, a GIP/GLP-1/glucagon receptor triagonist, produced dose-dependent mean weight reductions reaching 24.2% at 48 weeks in adults with obesity, with a safety profile consistent with the incretin class.

Retatrutide Human RCT
2023
Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526. View source
New England Journal of Medicine

Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV

The pivotal trial supporting FDA approval of tesamorelin: in HIV patients with abdominal fat accumulation, tesamorelin significantly reduced visceral adipose tissue and triglycerides over 26 weeks without worsening glucose tolerance.

Tesamorelin Human RCT
2007
Falutz J, et al. N Engl J Med. 2007;357(23):2359-2370. View source
Obstetrics & Gynecology

Bremelanotide for Hypoactive Sexual Desire Disorder (RECONNECT)

Two phase 3 randomized trials supporting FDA approval of bremelanotide (PT-141): the melanocortin agonist significantly improved sexual desire and reduced associated distress in premenopausal women with HSDD.

Bremelanotide (PT-141) Human RCT
2019
Kingsberg SA, et al. Obstet Gynecol. 2019;134(5):899-908. View source
The Lancet

Once-Weekly Cagrilintide for Weight Management — A Phase 2 Trial

The long-acting amylin analogue cagrilintide produced dose-dependent weight loss up to 10.8% over 26 weeks in adults with overweight or obesity, supporting amylin agonism as a distinct anti-obesity mechanism.

Cagrilintide Human RCT
2021
Lau DCW, et al. Lancet. 2021;398(10317):2160-2172. View source
Cell Metabolism

The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance

The foundational MOTS-c paper: this mitochondrial-derived peptide regulates the folate–AMPK pathway, enhancing insulin sensitivity and protecting against diet-induced obesity in mouse models.

MOTS-c Animal Study
2015
Lee C, et al. Cell Metab. 2015;21(3):443-454. View source
International Journal of Molecular Sciences

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

A comprehensive review of the copper tripeptide GHK-Cu, documenting its modulation of thousands of human genes toward tissue remodeling, wound healing, anti-inflammatory and antioxidant activity.

GHK-Cu In Vitro Human Study
2018
Pickart L, Margolina A. Int J Mol Sci. 2018;19(7):1987. View source
Critical Care

The Efficacy of Thymosin Alpha-1 for Severe Sepsis (ETASS): a multicenter, randomized controlled trial

In 361 patients with severe sepsis, thymosin alpha-1 produced a reduction in 28-day all-cause mortality and improved monocyte HLA-DR expression, supporting its immunomodulatory role.

Thymosin Alpha-1 Human RCT
2013
Wu J, et al. Crit Care. 2013;17(1):R8. View source
Current Pharmaceutical Design

Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease and Healing

A review of the extensive preclinical literature on BPC-157, summarizing its angiogenic, cytoprotective and tendon/ligament/gut healing effects across numerous rodent injury models.

BPC-157 Animal Study
2018
Sikiric P, et al. Curr Pharm Des. 2018;24(18):1990-2001. View source
Bulletin of Experimental Biology and Medicine

Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell Cultures

The Khavinson group reported that the tetrapeptide Epitalon (Epithalon) induced telomerase activity and telomere elongation in human somatic cells, allowing them to surpass the Hayflick division limit in culture.

Epithalon In Vitro Human Study
2003
Khavinson VK, et al. Bull Exp Biol Med. 2003;135(6):590-592. View source
Journal of Clinical Endocrinology & Metabolism

Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295, a Long-Acting Analog of GHRH, in Healthy Adults

Single injections of CJC-1295 produced sustained, dose-dependent increases in growth hormone (2–10×) and IGF-I lasting 6+ days, with a half-life supporting once-weekly dosing.

CJC-1295 Human Clinical Study
2006
Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. View source
European Journal of Endocrinology

Ipamorelin, the First Selective Growth Hormone Secretagogue

Ipamorelin stimulated growth hormone release with potency comparable to GHRP-6 but without the ACTH and cortisol elevations seen with other secretagogues, defining its selective profile.

Ipamorelin Animal Study
1998
Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. View source
Nature

Thymosin β4 Activates Integrin-Linked Kinase and Promotes Cardiac Cell Migration, Survival and Repair

Thymosin beta-4 (the parent of TB-500) promoted cardiomyocyte survival and migration and improved cardiac function after coronary artery ligation in mice, establishing its tissue-repair signaling.

TB-500 (Thymosin β4) Animal Study
2004
Bock-Marquette I, et al. Nature. 2004;432(7016):466-472. View source
Journal of Clinical Endocrinology & Metabolism

The Effects of a Synthetic Fragment of Human Growth Hormone (AOD-9604) on Lipid Metabolism

The C-terminal hGH fragment AOD-9604 stimulated lipolysis and inhibited lipogenesis in vitro and in obese animal models without the diabetogenic effects of intact growth hormone.

AOD-9604 Human Clinical Study
2001
Ng FM, et al. J Clin Endocrinol Metab. 2001;86(5):2009-2014. View source
Cellular Immunology

A Comprehensive Summary of LL-37, the Factotum Human Cathelicidin Peptide

A review of LL-37, the only human cathelicidin, detailing its broad-spectrum antimicrobial activity, immunomodulation, angiogenesis and wound-healing roles.

LL-37 In Vitro Human Study
2012
Vandamme D, et al. Cell Immunol. 2012;280(1):22-35. View source
Zh Nevrol Psikhiatr Im S.S. Korsakova

Efficacy and Safety of the Anxiolytic Selank in the Treatment of Generalized Anxiety and Neurasthenia

In a comparative clinical study, the heptapeptide Selank showed anxiolytic efficacy comparable to benzodiazepines (medazepam) without the sedation, dependence or withdrawal liabilities.

Selank Human Clinical Study
2008
Zozulia AA, et al. Zh Nevrol Psikhiatr. 2008;108(4):38-48. View source
Journal of Histochemistry & Cytochemistry

Semax, an Analogue of ACTH(4-10), Increases BDNF Levels in the Rat Hippocampus

Intranasal Semax elevated BDNF and trkB expression in the hippocampus, providing a molecular basis for its reported neuroprotective and cognitive-enhancing effects.

Semax Animal Study
2006
Dolotov OV, et al. J Histochem Cytochem. 2006;54(11):1289-1291. View source


Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.